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ABSTRACT: Osteoporosis is a common skeletal disease, affecting millions of individuals worldwide. Currently used
osteoporosis treatments substantially reducevertebral fracture risk,whereasnonvertebral fracture risk,mainly caused
byreducedcorticalbonemass,hasonlymoderatelybeen improvedby theosteoporosisdrugsused,defininganunmet
medical need. Because several wingless-type MMTV integration site family members (WNTs) and modulators of
WNT activity are major regulators of bone mass, we hypothesized that NOTUM, a secreted WNT lipase, might
modulate bonemass via an inhibition ofWNTactivity. To characterize the possible role of endogenousNOTUMas a
physiologic modulator of bone mass, we developed global, cell-specific, and inducible Notum-inactivated mouse
models. Notum expression was high in the cortical bone in mice, and conditional Notum inactivation revealed that
osteoblast lineage cells are the principal source of NOTUM in the cortical bone. Osteoblast lineage–specific Notum
inactivation increased cortical bone thicknessvia an increasedperiosteal circumference. InducibleNotum inactivation
in adult mice increased cortical bone thickness as a result of increased periosteal bone formation, and silencing of
Notum expression in cultured osteoblasts enhanced osteoblast differentiation. Large-scale human genetic analyses
identified genetic variants mapping to the NOTUM locus that are strongly associated with bone mineral density
(BMD) as estimated with quantitative ultrasound in the heel. Thus, osteoblast-derived NOTUM is an essential local
physiologic regulator of cortical bonemassvia effects onperiosteal bone formation in adultmice, andgenetic variants
in the NOTUM locus are associated with BMD variation in adult humans. Therapies targeting osteoblast-derived
NOTUMmay prevent nonvertebral fractures.—Move´rare-Skrtic, S., Nilsson, K. H., Henning, P., Funck-Brentano, T.,
Nethander,M., Rivadeneira, F., ColettoNunes, G., Koskela, A., Tuukkanen, J., Tuckermann, J., Perret, C., Souza, P. P.
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Osteoporosis is a common skeletal disease, affecting
millions of individualsworldwide, and the prevention of
fractures is an important public health goal. Currently,
the osteoporosis treatments that are used substantially
reduce vertebral fracture risk, whereas nonvertebral
fracture risk has only moderately been improved by the
osteoporosis drugs used, defining an unmet medical
need (1, 2). Although cortical bone mass and composi-
tion are major determinants of bone strength and frac-
ture risk in humans (1, 3, 4), only a limited number of
studies have focused on the cellular and molecular
mechanism specifically regulating cortical bonemass (2).
However, it is known that the periosteal surface of the
cortical bone is regulatedbygrowthhormone (GH), insulin-
like growth factor I (IGF-I), and periostin (5–8).
Wingless-typeMMTV integration site family members
(WNTs) belong to a family of secreted cysteine-rich gly-
coproteins that signal via either the WNT/b-catenin
pathway, also termed the canonical WNT pathway, or the
noncanonical WNT pathways. A crucial step for WNT
signaling is the interaction between WNTs and their
transmembrane receptor proteins frizzled. When WNT
proteins are synthesized, an acyl group from palmitoleic
acid is attached at a serine amino acid residue (9). This lipid
modification of WNT is necessary for its function because
the frizzledproteins containacleft that specifically interacts
with the acyl group. Recent in vitro studies have demon-
strated that an extracellular enzyme (secreted lipase) called
NOTUM renders WNT inactive by specifically removing
the acyl group fromWNT (9, 10). It has beendescribed that
NOTUM is a circulating protein, but the relative impor-
tance of circulating vs. local NOTUM is unknown (11). In a
previous report, lifelong NOTUM inactivation in mice,
using the less precise gene trapping technique, resulted in
developmental defects involving the kidneys (unilateral
agenesis) and teeth (dental dysplasia) as well as reduced
embryonic viability (12). Referring to this mouse model of
NOTUM inactivation, developed in a large-scale screen of
multiple mouse models, it was recently reported that the
mice surviving to adulthood had increased cortical bone
mass, but the underlying mechanisms for the skeletal
phenotype in these mice were not evaluated (13).
Because several WNTs and modulators of WNT activity
are major regulators of bone mass (1, 4, 14, 15), we hypothe-
sized that NOTUM might modulate bone mass via an inhi-
bition of WNT activity. To characterize the possible role of
endogenous NOTUM as a physiologic modulator of bone
mass,wedevelopedglobal, cell-specific,andinducibleNotum-
inactivatedmousemodels using homologous recombination,
allowing precise manipulation of genetic sequences in the
mouse. In addition,wedetermined the cellular andmolecular
effects of Notum using cultured osteoblasts and osteoclasts.
Finally, we aimed to determine if genetic variation in the
NOTUM locus is associated with bone mass in humans.
MATERIALS AND METHODS
Generation of global Notum2/2 and Notum+/2 mice
The global Notum2/2 and Notum+/2 mice were generated by
breeding male Notumflox/flox mice (kindly provided by Prof.
ChristinePerret, INSERM, InstitutCochin) (16),with femalemice
expressing Cre recombinase ubiquitously and from an early
embryonic stage under the control of the phosphoglycerate
kinase-1 promoter (PGKcre) (17). In PGKcre-expressing female
mice, theCre activity starts in the diploidphase of oogenesis, and
thereby a complete recombination of LoxP sites occurs also in
Cre2 offspring. In the Notumflox mice, LoxP sites are introduced
upstream fromNotum exon 2 anddownstream fromNotum exon
8 and in the presence of an active Cre recombinase, the DNA
fragment from exon 2 to exon 8 of theNotum gene is excised (16).
Presence or absence of theNotumflox allelewas determinedbyuse
of multiplex real-time PCR analysis (StepOnePlus Real-Time
PCRSystem, Thermo Fisher Scientific,Waltham,MA,USA). The
following primers and carboxyfluorescein-labeled probe were
used for detection of the Notumflox allele: forward (59-CCAT-
GATCCTGTGCCTTTCT-39), reverse (59-CGACGCGTGAA-
GTTCCTATT-39), and probe (59-GGCCGCGAAGTTCCTATACT-
39), whereas the following primers andVIC-labeled probewere
used for detection of the Notum+ allele: forward (59-CCAT-
GATCCTGTGCCTTTCT-39), reverse (59-AGTGGCATCGG-
AGACAAATC-39), and probe (59-TTGGCAGCCCCAAAATA-
TAG-39). Genotyping for the presence of PGKcre was done
using forward (59-AACATGCTTCATCGTCGG-39) and primer
(59-TTCGGATCATCAGCTACACC-39).
Briefly, male Notumflox/flox mice were bred with PGKcre-
expressing female mice generating Notum+/2 offspring. To gen-
erateNotum2/2, Notum+/2, and littermatewild-type (WT) control
mice for the experiment, Notum+/2 female and male mice were
mated. Male and female mice included in the experiment were
euthanized at 15 wk of age.
The degree of Notum deletion at the DNA level in different
tissues was determined by multiplex real-time PCR analysis us-
ing the following primers and carboxyfluorescein-labeled probe:
forward (59-TGGCTTCCCAGCCCATTAAG-39), reverse (59-
GGCATGCTACAGACAGGTTG-39), and probe (59-AGTC-
TCACCACCCTGCCCTGT-39). The following primers and
VIC-labeled probe were used as a reference because they detect a
sequence present in all mice: forward (59-AGGTCTCAGA-
CGGCAATCAT-39), reverse (59-CCTCCACTGCCTGCTAAG-
AT-39), and probe (59-ACCCAGCATGGTGAGGCCTGCC-39).
Generation of Runx2cre-Notumflox/flox mice
To generate specific inactivation ofNotum in the osteoblast line-
age, Notumflox/flox mice were bred with the previously described
Runx2-cre mice (2, 18). These Runx2-creNotumflox/flox mice dis-
play early osteoblast-specific Cre expression and have the ca-
pacity to recombine LoxP-flanked DNA sequences in an early
osteoblast-specificmanner, andanefficient recombinationoccurs
at all sites of endochondral and intramembranous bone forma-
tion (particularly in periosteal cells, osteoblasts, and osteocytes
but not osteoclasts) when Runx2-cre mice were crossed to a
Rosa26 reporter strain (18). To generate mice depleted of
Notum in osteoblasts, female mice with 2 floxedNotum alleles
(Notumflox/flox) were mated with male mice having 1 floxed
Notum allele and 1 allele of Runx2-cre (Runx2-creNotum+/flox).
The littermate control mice were Notumflox/flox. Runx2-cre
mice have an unchanged skeletal phenotype compared toWT
mice (2). Genotyping of Notumflox mice was performed as
described above, whereas the presence of the Runx2-cre gene
was determined using a 3-primer strategy. The common 59
primer (59-CCAGGAAGACTGCAAGAAGG-39) binds to the
Runx2 promoter of the endogenous gene and the transgene.
The 39 primer (59-TGGCTTGCAGGTACAGGAG-39) binds to
the Cre sequence, and another 39 primer (59-GGAGCTGCC-
GAGTCAATAAC-39) binds to the endogenous Runx2. Male
and female Runx2-creNotumflox/flox mice included in the ex-
periment were euthanized at 17 wk of age.
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Generation of mice with inducible
Notum inactivation
In order to study the acute adult effects of Notum, avoiding
confounding developmental effects, inducible Notum knockout
mice were created by breeding the Notumflox/flox mice with
the previously described B6.Cg-Tg(CAG-Cre/Esr1*)5Amc/J
(CAGGCre-ER, 004682; The Jackson Laboratory, Bar Harbor,
ME, USA) transgenicmice (19). Briefly, a male transgenic mouse
expressing a tamoxifen-inducible Cre-mediated recombinase,
and aNotum+/flox allele (hereafter called CAGGCre-ER-Notum+/flox)
were bred with female Notumflox/flox mice, creating CAGGCre-ER-
Notumflox/flox mice. Notumflox/flox littermates were used as
controls. Genotyping of the Notumflox/flox mice was done as
previously described, and the presence of the Cre construct
was determined using the following primers: Cre forward:
Figure 1.Heterozygous female Notum-inactivated mice have increased cortical bone thickness. A) Schematic drawing of the global
Notum-inactivated mouse model. B) Normal body weight in both male and female Notum+/2 mice (n = 8) when comparing with
WT mice (n = 7) at 4, 6, and 13 wk of age. C) Notum+/2mice (n = 8) have normal femur length compared to WT mice (n = 7). D)
Soft tissue weights over body weight in male and female Notum+/2 (n = 8) and WT (n = 7) mice. E) mRNA expression analyses of
Notum in liver, cortical bone, vertebral body, spleen, and gonadal fat, as normalized to WT liver, in male Notum+/2 (n = 8) and WT
(n = 7) mice. F) Degree of deletion in puriﬁed DNA from male WT (n = 7), Notum+/2 (n = 8), and Notum2/2 (n = 2) mice in
cortical bone and liver. G, H) Femur BMD (females, G) and total body BMD (H) as measured by DXA in Notum+/2 (female, n =
8) and WT mice (female, n = 7). I–M) Cortical bone area (I), cortical thickness (J ), mean polar moment of inertia (K), cortical
porosity (L), and cortical volumetric BMD (M) of the femur as measured by mCT in female Notum+/2 (n = 8) and WT (n = 7)
mice. N) Maximal load (F max) of the humerus as measured by 3-point bending analyses in female Notum+/2 (n = 8) and WT (n =
7) mice. O, P) Trabecular bone volume/tissue volume (BV/TV) of the femur (O) and of the vertebrae L5 (P) as measured by
mCT in female Notum+/2 (n = 8) and WT (n = 7) mice. Unless otherwise stated, the results refer to 13-wk-old mice. N.D., not
detectable; Sem Ves, seminal vesicles. All values are given as means6 SEM. (*)P = 0.09, *P, 0.05, **P, 0.01, ***P, 0.001 vs.WT
mice (Student’s t test).
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59-GCGGTCTGGCAGTAAAAACTATC-39; Cre reverse: 59-GT-
GAAACAGCATTGCTGTCACTT-39; WT forward: 59-CTA-
GGCCACAGAATTGAAAGATCT-39; and WT reverse: 59-
GTAGGTGGAAATTCTAGCATCATCC-39.
To study the adult effects of NOTUM on cortical bone thick-
ness and bone strength, avoiding confounding developmental
effects, a long-term study using femaleCAGGCre-ER-Notumflox/flox
mice was performed. Female 11-wk-old CAGGCre-ER-
Notumflox/flox and Notumflox/flox littermate control mice were
injected with tamoxifen (50 mg/kg; T5648; MilliporeSigma,
Burlington, MA, USA) for 3 consecutive days to activate the Cre
construct. The mice were euthanized 31 d after the first tamoxifen
injectionat theageof 15wk.Tomechanistically study the importance
of NOTUM in a short-term study, 20-wk-old male CAGGCre-ER-
Notumflox/flox and Notumflox/flox littermate control mice were injected
with tamoxifen for 3 consecutive days. The mice were euthanized
11 d after the first tamoxifen injection at the age of 22 wk.
The experimental procedures involving animals were ap-
provedby theEthicsCommittee at theUniversityofGothenburg,
and the care of the animalswas in accordancewith its guidelines.
Themicewere housed in a standard animal housing facilitywith
12-h dark/light periods. The temperaturewas controlled (22°C),
and food and water were available ad libitum. At termination,
the animals were anesthetized with Ketador/Dexdomitor
(Richter Pharma, Wels, Austria/Orion Oyj, Espoo, Finland),
bled, and euthanized by cervical dislocation. Long bones and
vertebrae were dissected and stored for future analyses, and
soft tissueswere collected,weighed, and snap-frozen in liquid
nitrogen.
Assessment of murine bone parameters
Dual-energy X-ray absorptiometry
Total bodyand femurbonemineraldensity (BMD)wereassessed
using Lunar PIXImus densitometer (Wipro GE Healthcare,
Chicago, IL, USA), or the UltraFocusDXA (Faxitron Bioptics,
Tucson, AZ, USA) (2, 20).
High-resolution micro–computed tomography
High-resolution micro–computed tomography (mCT) was used
toanalyzedistal femur,proximal tibia, andvertebraeL5 (Skyscan
Figure 2. Osteoblast-derived NOTUM is the principal source of NOTUM in bone. A) Schematic drawing of the conditional
osteoblast lineage–speciﬁc Notum-inactivated mouse model. B) Degree of deletion of Notum DNA in cortical bone and liver in
Runx2-creNotumﬂox/ﬂox (n = 15) and Notumﬂox/ﬂox (n = 11) male mice. C) mRNA expression analyses of Notum in the cortical bone
and liver in Runx2-creNotumﬂox/ﬂox (females, n = 11; males, n = 15) and Notumﬂox/ﬂox (females, n = 13; males, n = 11) mice. D) mRNA
expression analyses of Notum in cultured calvarial osteoblasts (cOBL) and bone marrow macrophage–derived osteoclasts
(BMMOCLs) from Runx2-creNotumﬂox/ﬂox and Notumﬂox/ﬂox mice. (Representative experiment, n = 3 wells/cell type and mouse
strain.) E) Normal body weight in Runx2-creNotumﬂox/ﬂox mice (female, n = 11; male, n = 15) compared to Notumﬂox/ﬂox mice
(female, n = 13; male, n = 11) at 5, 12, and 17 wk of age. F) Normal femur length in Runx2-creNotumﬂox/ﬂox mice (female, n = 11;
male, n = 15) compared to Notumﬂox/ﬂox mice (female, n = 13; male, n = 11). G) Soft tissue weights over body weight in Runx2-
creNotumﬂox/ﬂox mice (females, n = 11; males, n = 15) and Notumﬂox/ﬂox mice (females, n = 13; males, n = 11). H) Total body BMD as
measured by DXA in 5-wk-old and 17-wk-old Runx2-creNotumﬂox/ﬂox mice (female, n = 11; male, n = 15) and Notumﬂox/ﬂox mice
(female, n = 13; male, n = 11). I) Femur BMD as measured by DXA in 17-wk-old Runx2-creNotumﬂox/ﬂox mice (female, n = 11; male,
n = 15) and Notumﬂox/ﬂox mice (female, n = 13; male, n = 11). Unless otherwise stated, the results refer to 17-wk-old mice. All values
are given as means 6 SEM. *P , 0.05, **P , 0.01 vs. Notumﬂox/ﬂox mice (Student’s t test).
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1172; Bruker MicroCT, Aartselaar, Belgium) (2). The cortical re-
gion was analyzed in the diaphyseal region of femur and tibia,
starting at a distance of 5.2 mm from the growth plate and
continuing a further 134 mm in proximal direction for femur and
in the distal direction for tibia. Trabecular bone was analyzed in
themetaphyseal region of the femur and tibia, starting650 mm
from the growth plate and continuing a further 134 mm in
proximal direction for femur and in distal direction for tibia. In
the L5 vertebral body, the trabecular bone caudal of the pedicles
was selected for analysis commencing at a distance of approx.
4.5 mm caudal of the lower end of the pedicles, and extending a
further longitudinal distance of 230 mm in the caudal direction.
Within the trabecular region, the trabecular bone was manually
separated from the cortical bone by contouring the irregular an-
atomic structure adjacent to the endocortical boundary on a
slice-by-slice basis. ThegrayscalemCT imageswereprocessed by
a global threshold segmentation using the CTAn software
(Bruker MicroCT) (2).
Peripheral quantitative computed tomography
Computed tomography (CT) scans were performed using the
peripheral quantitative computed tomography XCTResearchM
(v.4.5B; Norland Stratec, Pforzheim, Germany) with a voxel size
of 70 mm, as previously described by Windahl et al. (21). To
measure trabecular volumetric BMD, the scan was positioned in
the metaphysis of the femur at a distance corresponding to 3.4%
of the total femur length, proximal from the distal growth plate.
This area contained trabecular and cortical bone, and the
trabecular region was therefore defined as the inner 45% of the
total cross-sectional area. The cortical bone parameters were an-
alyzed in themiddiaphyseal region of the femur,which is an area
that contains only cortical bone. The threshold for cortical bone
was set to 710 mg/cm3 (22).
Mechanical strength
After dissection, the humerus was frozen at220°C. Three-point
bending was performed with a span length of 4.5 mm and a
loading speed of 0.155 mm/s using an Instron 3366 (Instron,
Norwood, MA, USA). Biomechanical parameters, based on the
recorded load deformation curves, were calculated fromBluehill
2 software v.2.6 (Instron) with custom-made Excel (Microsoft,
Redmond, WA, USA) macros (2).
Bone histomorphometry
For dynamic histomorphometry, themicewere intraperitoneally
injected with the fluorochromes calcein and alizarin (Merck
GmbH, Darmstadt, Germany) 9 and 2 d prior to termination,
respectively (2). Upon dissection, femur and tibia were fix-
ated in 4% formaldehyde, dehydrated in 70% EtOH, and
imbedded in methyl methacrylate. The femur and tibia were cut
in 200-mm-thick transverse cross-sectional sections in the
middiaphyseal region (for dynamic cortical histomorphometry),
as well as in 4-mm-thick longitudinally coronary sections (for
static histomorphometry). The analyses of dynamic cortical bone
TABLE 1. Increased cortical bone mass in mice with inducible Notum inactivation
Variable Notumﬂox/ﬂox CAGG-Cre-ER-Notumﬂox/ﬂox
DXA
Femur BMD (mg/cm2) 104.2 6 1.8 109.2 6 1.5*
Total body BMD (mg/cm2) 73.2 6 0.8 75.4 6 0.7#
CT (tibia)
Cortical bone area (mm2) 0.87 6 0.02 0.93 6 0.02*
Cortical bone thickness (mm) 222 6 5 234 6 3*
Mean polar moment of inertia
(mm4)
0.33 6 0.01 0.37 6 0.02*
Cortical porosity (%) 6.4 6 0.8 5.8 6 0.6
Cortical volumetric BMD (g/cm3) 1.22 6 0.02 1.23 6 0.02
Trabecular bone volume/tissue
volume (%)
20.1 6 1.5 21.6 6 0.7
Values are given as means 6 SEM. (Notumﬂox/ﬂox, n = 10; CAGG-Cre-ER-Notumﬂox/ﬂox, n = 12; 15-wk-old
female mice; #P = 0.056). *P , 0.05 vs. Notumﬂox/ﬂox (Student’s t test).
TABLE 2. Increased number of periosteal osteoblasts in mice with inducible Notum inactivation
Variable Notumﬂox/ﬂox CAGG-Cre-ER-Notumﬂox/ﬂox
Periosteal
Number of osteoblasts/perimeter (mm21) 1.9 6 0.6 5.6 6 1.3*
Osteoblast surface/bone surface (%) 4.0 6 1.3 11.5 6 2.7*
Number of osteoclasts/perimeter (mm21) 0.8 6 0.1 0.9 6 0.1
Osteoclast surface/bone surface (%) 2.7 6 0.4 2.7 6 0.4
Endocortical
Number of osteoblasts/perimeter (mm21) 23.3 6 2.7 18.0 6 2.1
Osteoblast surface/bone surface (%) 46.4 6 5.8 34.5 6 4.1
Number of osteoclasts/perimeter (mm21) 1.3 6 0.2 1.2 6 0.2
Osteoclast surface/bone surface (%) 4.1 6 0.7 3.4 6 0.5
Values are given as means 6 SEM. (Notumﬂox/ﬂox, n = 12; CAGG-Cre-ER-Notumﬂox/ﬂox, n = 10; 22-wk-old
male mice). *P , 0.05 vs. Notumﬂox/ﬂox (Student’s t test).
OSTEOBLAST-DERIVED NOTUM REDUCES CORTICAL BONE MASS 11167
Downloaded from www.fasebj.org by (145.5.176.8) on October 09, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 11163-11179.
parameters were performed without any staining. For analyses
of cellular parameters, the 4-mm-thick sections were stained
with Masson-Goldner trichrome. Osteoclasts were defined in
Masson-Goldner trichrome–stained sections as bone-resorbing
multinucleated cells (2 or more nuclei) in contact with cortical
bone surface. The bone-resorbingnaturewas identified using the
shape of the cell (compared to other endosteal cells, including flat
mononuclear bone lining cells and cuboidal mononuclear oste-
oblasts) and the possible presence of eroded surface (23, 24). All
parameters were measured using the OsteoMeasure Histo-
morphometry Analysis System software v.2.2 (Osteometrics,
Atlanta, GA, USA), following the guidelines of the American
Society for Bone and Mineral Research (25).
Measurement of serum markers
To assess bone resorption, serum levels of C-terminal type I col-
lagen (CTX) fragments were measured using an ELISA RatLaps
Kit (Immunodiagnostic Systems, East Boldon, United Kingdom).
Serum levels of procollagen type I N-terminal propeptide were
measured using a Rat/Mouse EIA Kit (Immunodiagnostic Sys-
tems) as a marker of bone formation.
Cell cultures
Silencing of Notum in MC3T3-E1 osteoblasts
Gene expression analyses in primary calvarial cell cultures from
WT mice showed that expression of Notum mRNA was
down-regulated during culture to an expression level similar to
that in cells from Runx2-creNotumflox/floxmice (Supplemental Fig.
S1A). The mRNA expression of Notum was also decreased in
primary cultures of osteoblasts from long bones (Supplemental
Fig. S1B). This finding, together with the fact that these cells are
a mixture of Runx2-expressing cells and other cell types present
in the bones used for isolation, made us select the murine
preosteoblastic cell line MC3T3-E1 for studies on the role of en-
dogenous NOTUM in osteoblast differentiation. An important
observation for this selection was the finding that the Notum
mRNA expression in the MC3T3-E1 cells was not decreased in
cell cultures over 11 d (Supplemental Fig. S2), in contrast to pri-
mary bone cell cultures.
MC3T3-E1 (CRL-2593, subclone 4; American Type Culture
Collection, Manassas, VA, USA)was maintained in a-minimum
essential medium (a-MEM, M0450; Thermo Fisher Scientific;
MilliporeSigma) supplemented with 10% heat inactivated fetal
bovine serum (16000-044; Thermo Fisher Scientific), 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
For experiments, cells were seeded at an initial density of 10,000
cells in 500 ml of culture medium in 48-well culture dishes
(Corning, Corning, NY, USA). To induce osteogenic differ-
entiation, osteogenic medium was prepared by further sup-
plementation with 50 mg/ml L-ascorbic acid and 4 mM
b-glycerophosphate (MilliporeSigma). Mediumwas replaced
every 2 d for the duration of all experiments. All cells were
maintained at 37°C in a humidified 5% CO2 environment.
To assess the role of NOTUM in osteoblast differentiation,
Notum mRNA was silenced using a specific small interfering
RNA (siRNA) sequence (Invitrogen Silencer Predesigned siRNA
4390771, S95064; Thermo Fisher Scientific). A scrambled se-
quence (AM4635)wasusedasnegative control. Twenty-four and
72 h after seeding, the cells were transfected with 30 nM of the
siRNA using lipofectamine RNAiMax (Thermo Fisher Scientific)
in serum-free OptiMEM (Thermo Fisher Scientific). Cells were
harvested 24 h after the first and second transfection for gene
expression analyses. For quantification of alkaline phosphatase
(ALP) activity andALPstaining, cellswereexposed toosteogenic
media 24hafter the secondsilencing,withanadditional silencing
3 d later. Seven days after exposure to osteogenic media, cells
were stained for ALP and enzyme activity was analyzed
quantitatively.
ALP analyses
At the end of osteogenic treatment, the cells were fixedwith 70%
ethanol for 10 min and stained for ALPase activity using a
commercial kit (86R; MilliporeSigma) following the manufac-
turer’s instructions and photographed. For quantification of
ALPase activity, proteins from another plate were extracted us-
ing 200 ml of ultrapure water and exposed to 5 thermal shock
cycles for 20 min at 220°C and 15 min at 37°C. Proteins were
quantified using Bicinchoninic Acid Assay Kit (23235; Thermo
Fisher Scientific). For ALPase activity measurement, a commer-
cial kit based on the ability of ALP to hydrolyze thymolphthalein
monophosphate releasing thymolphthalein was used (Labtest
Diagnostica, Lagoa Santa, Brazil). Briefly, 10mg of proteins were
used in a final volume of 80 ml of the reaction buffer (pH 10.1)
containing 2.75 mM of thymolphthalein monophosphate and
incubated at 37°C for 90 min in a 96-well ELISA plate (Corning).
After the reaction period, 200 ml of color reagent was added to
each well and the absorbance was measured at 580 nM using a
spectrophotometer (Epoch; Biotek, Winooski, VT, USA).
Primary bone cell cultures
Primary calvarial periosteal bone cells from3- to 5-d-old C57BL/
6NNotumflox/flox andRunx2-creNotumflox/floxmicewere isolated by
sequential enzymatic digestion aspreviouslydescribed in refs. 26
and 27. Isolated periosteal bone cells were cultured in com-
pletea-MEM(22561-021; ThermoFisher Scientific) supplemented
with 10% heat inactivated fetal bovine serum (F7524;
MilliporeSigma), 2 mM GlutaMax (35050-038; Thermo Fisher
Scientific), 50 mg/ml gentamicin (15750-037; Thermo Fisher
Scientific), 100 U/ml penicillin and 100 mg/ml streptomycin
(15140-148; Thermo Fisher Scientific) for 3–5 d prior to experi-
ment start. At the start of the experiment, cells were seeded at
20,000 cells/cm2 in 48 well plates and incubated in osteo-
genic media [complete a-MEM supplemented with 10 mM
b-glycerophosphate disodium salt hydrate (BGP, G9422;
MilliporeSigma) and 0.2 mM L-ascorbic acid 2-phosphate
sesquimagnesium salt hydrate (Asc-2P, A8960; MilliporeSigma)].
Culturemediawere replenishedafter 4d and cellswereharvested
for RNA analysis after 4 and 7 d of culture. Primary bone cell
cultures from femur and tibia from 8- to 12-wk-old C57BL/6N
micewere isolated by outgrowth of cells from collagenase-treated
diaphyseal cortical bone as previously described by Bakker and
Klein-Nulend (27). Primary bone cells from femur and tibia were
isolated in complete a-MEM, and thereafter experiments were
performed in osteogenicmediumas for calvarial bone cells above.
Primary osteoclast cell cultures
Bonemarrow cells from 8- to 12-wk-oldNotumflox/flox andRunx2-
creNotumflox/flox mice were cultured in suspension culture discs
(Corning) in complete a-MEM with 30 ng/ml macrophage
colony-stimulating factor (M-CSF) (416-ML-050; R&D Systems,
Minneapolis, MN, USA) for 2 d, and the adherent bone
marrow–derived macrophages (BMMs) were used as osteoclast
progenitors (28, 29). BMMs were detached and spot seeded in
24-well plates (40,000 cells/well) and cultured in complete
a-MEM with 30 ng/ml M-CSF with or without the addition of
4 ng/ml receptor activator of nuclear factor k-B ligand (RANKL)
(462-TEC; R&D Systems) to induce osteoclast differentiation. The
medium was changed after 3 d and cells harvested for RNA iso-
lation by lysis in RLT buffer (Qiagen, Germantown, MD, USA)
4 d after seeding.
11168 Vol. 33 October 2019 MOVE´RARE-SKRTIC ET AL.The FASEB Journal x www.fasebj.org
Downloaded from www.fasebj.org by (145.5.176.8) on October 09, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 11163-11179.
Treatment of osteoclasts with recombinant NOTUM
Osteoclasts were differentiated from BMMs as described above.
Cells were cultured in M-CSF and RANKL with or without
the addition of 10 or 100 ng/ml recombinant human NOTUM
(9118-NM;R&DSystems) for 3–4dbefore staining for expression
of tartrate-resistant acidphosphatase (TRAP)usinga commercial
staining kit (387A; MilliporeSigma) or lysis in RLT buffer for
RNA purification. To study osteoclast formation and activity on
bone, 20,000BMMswere seededonbovinebonediscs (IDSNordic,
Copenhagen,Denmark) in96-wellplates.Mediawerechangedand
saved for analysis every 3–4 d, and staining for TRAP was per-
formedafter 10d.The total amountofTRAP5b in the culturemedia
were analyzed as a measure of osteoclastogenesis using a com-
mercial kit (IDS Nordic). Resorptive activity, as assessed by the
release of C-terminal telopeptides of type I collagen (CTX-I) from
the bone slices, was measured using commercial CTX ELISA (IDS
Nordic).
Lipase activity measurement of
recombinant NOTUM
Functional enzyme activity of recombinanthumanNOTUMwas
tested using the fluorogenic substrate 8-Octanoyloxypyrene-1-
3-6-trisulfonic acid trisodium salt (74875; MilliporeSigma).
Recombinant NOTUM (50 ng) dissolved in 0.1% bovine serum
albumin in PBS (25ml) wasmixedwith an equal volume of 5mM
8-Octanoyloxypyrene-1-3-6-trisulfonic acid trisodium salt in 2
times reaction buffer (10 mM CaCl2, 1 mM MgCl2, 50 mM
TrisHCl, pH7.4). Fluorescence intensity at 535nmwasmeasured
after 10, 20, and 30 min using a SpectraMax i3 (Molecular De-
vices, Sunnyvale, CA, USA). Wheat germ lipase (L3001, 250 ng;
MilliporeSigma) was used as positive control and 0.1% bovine
serum albumin in PBS was used as blank.
Real-time quantitative PCR
Total mRNA was prepared from bone using Trizol reagent
(15596018; ThermoFisher Scientific) andRNeasyMiniKit (74106;
Qiagen). For preparation of total mRNA from cultured cells,
the RNeasy Micro Kit (74004; Qiagen) or Total RNA Purifica-
tion Kit (DPK-108L; Cellco, Basking Ridge, NJ, USA) were used.
The mRNA was reversed transcribed into cDNA (4368814;
Thermo Fisher Scientific), and real-time PCR analyses were per-
formed using the StepOnePlus Real-Time PCR System (Thermo
Fisher Scientific) and Assay-on-Demand primer and probe
sets (Notum: Mm01253273_m1, Alpl: Mm00475834_m1, Acp5
(Trap): Mm00475698_m1, Nfatc1: Mm00479445_m1, Ctsk:
Mm00484036_m1; Thermo Fisher Scientific). The expression of
each gene was adjusted to 18S ribosomal subunit (4310893E;
Thermo Fisher Scientific) or Actb custom-made primers: forward
(59-GGACCTGACGGACTACCTCATG-39), reverse (59-TCTT-
TGATGTCACGCACGATTT-39), used as an internal standard.
All assays had 90–100% efficiency, thus the 22DDCt method
was used to calculate the relative gene expression.
Statistical analyses
Values are given as means 6 SEM. The statistical difference be-
tween Runx2-creNotumflox/flox mice and Notumflox/flox mice, be-
tween CAGGCre-ER-Notumflox/flox and Notumflox/flox mice, as well
as between Notum+/2mice and WT mice, were calculated using
an unpaired, 2-tailed Student’s t test. Statistical differences be-
tween cell culture treatment groups were calculated using an
unpaired, 2-tailed Student’s t testwhen therewere 2 groups (cells
from 2 mouse strains or 2 treatment groups) and using 1-way
ANOVAandTukey’smultiple comparison testwhen therewere
more than 2 treatment groups. A difference was considered sta-
tistically significant if P, 0.05.
Large-scale human genetic analyses
using the UK Biobank
In 2006–2010, theUKBiobank recruited 502,647 individuals aged
37–76 yr from across the United Kingdom. All participants pro-
vided information regarding their health and lifestyle via touch
screen questionnaires, consented to physical measurements, and
agreed to have their health followed. They also provided blood
for future analysis. UK Biobank has ethical approval from the
Northwest Multicenter Research Ethics Committee, and in-
formed consent was obtained from all participants.
Estimated BMD using ultrasound
Quantitative ultrasound of the heel was used to obtain a nonin-
vasive estimate of BMD that predicts fracture (30, 31). A Sahara
Clinical Bone Sonometer (Hologic,Marlborough,MA,USA)was
used for quantitative ultrasound assessment of calcanei in UK
Biobank participants. Details of the complete protocol are pub-
licly available on theUKBiobankwebsite (https://www.ukbiobank.
ac.uk/). Estimated BMD (eBMD; g/cm2) was derived as a linear
combination of speed of sound (SOS in the following equation)
and bone ultrasound attenuation (BUA in the following equa-
tion) [eBMD = 0.00259263 (BUA + SOS)2 3.687] (31).
Genotyping
Genotype data are available for488,000 participants in the UK
Biobank cohort.Genotypingwas performedusing theAffymetrix
UK BiLEVEAxiom array on an initial set of50,000 participants;
the remaining 450,000 participants were genotyped using
the Affymetrix UK Biobank Axiom array. The 2 arrays are ex-
tremely similar (with over 95% common content). Quality
control and imputation [toover 39millionHaplotypeReference
Consortium single nucleotide polymorphisms (SNPs) includ-
ing more than 8 million SNPs with a minor allele frequency
.1%] were performed centrally by UK Biobank. IMPUTE2
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html#home) was
used for imputation to the Haplotype Reference Consortium
v.1.1 panel.
Model used for genetic associations
The recently released version of BOLT-LMM Bayesian mixed
model association method (https://www.biorxiv.org/content/early/
2017/09/27/194944) was used for the associations between im-
puted SNPs and eBMD (on a BMD T-score scale). This method
was developed to produce highly powered, robust test statistics
when runonallEuropeansamples (retaining related individuals)
in the UK Biobank. The model was adjusted for sex, age, and
weight. The genome-wide association study of estimated ultra-
soundBMDusing thismethodologywas recentlymadeavailable
for public download (https://data.broadinstitute.org/alkesgroup/
UKBB/). For the present study, we used these downloaded data
and searched for possible associations specifically between im-
puted SNPs (minor allele frequency (MAF).1%) in theNOTUM
locus625kb from thegenes’ start/end limits and eBMD. In total,
125SNPswith aminor allele frequency.1%were tested, andwe
applied a conservative Bonferroni correction for these SNPs,
setting a value of P = 0.05/125 = 4.0 3 1024 as a significance
threshold.
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RESULTS
Heterozygous female Notum-inactivated mice
have increased cortical bone thickness
To determine the role of NOTUM in the skeleton, we de-
veloped a mouse model with global Notum inactivation
(Notum2/2). This model had exons 2–8 of theNotum gene
deleted (Notum2/2;Fig. 1A).AmajorityofNotum2/2mice
(90%) died during embryonal development, and the few
mice surviving until 13 wk of age were severely growth
inhibited. However, heterozygous Notum+/2 mice had
normal embryonic development and were born appar-
ently healthy and had a normal bodyweight growth until
13 wk of age (Fig. 1B). In addition, Notum+/2 mice
displayed normal bone length of femur (Fig. 1C) and
normal weights of several visceral organs (Fig. 1D). When
comparing the Notum expression in different tissues, the
highest expression inWTmice was observed for liver and
diaphyseal cortical bone (Fig. 1E). Notum+/2 mice had
reduced Notum mRNA levels in both liver and bone
compared with WT mice (Fig. 1E), and no Notum expres-
sion was observed in the few surviving severely
growth-inhibited Notum2/2 mice. As expected, the re-
combination of the Notum allele in liver and bone was
complete in theNotum2/2mice, and it was50% in these
2 tissues of Notum+/2mice (Fig. 1F).
Dual-energy X-ray absorptiometry (DXA) analyses
revealed that the total femur BMD was significantly in-
creased in femaleNotum+/2mice comparedwithWTmice
(Fig. 1G), and a similar nonsignificant trend was observed
for totalbodyBMD(Fig. 1H).Wenext evaluated thecortical
and trabecular bone compartments separately using
high-resolution mCT analyses. The femur middiaphyseal
cortical bone area (Fig. 1I), cortical thickness (Fig. 1J), and
the estimated bone strength polar moment of inertia (Fig.
1K) were significantly increased in female Notum+/2mice
compared with WT mice, whereas cortical porosity (Fig.
1L) andcortical volumetricBMD(Fig. 1M)wereunaffected.
Three-point bending analyses of the diaphyseal region of
the humerus revealed increased cortical bone strength in
femaleNotum+/2mice compared with WTmice (Fig. 1N).
In contrast, female Notum+/2 mice had normal trabecular
bone volume/tissue volume (BV/TV) fraction in both the
distal metaphyseal region of femur (Fig. 1O) and in the L5
vertebral body (Fig. 1P). Thus, heterozygous female No-
tum-inactivated mice have specifically increased corti-
cal bone thickness and bone strength. There was no
significant bone phenotype in the male Notum+/2mice
comparedwithmaleWTmice (Supplemental Table S1).
Osteoblast-derived NOTUM is the principal
source of NOTUM in bone
Because Notum expression was high in cortical bone, we
hypothesized that the cortical bone phenotype in the het-
erozygote femaleNotum-inactivatedmicemightbe caused
by lack of Notum expression by osteoblast lineage cells in
cortical bone. However, a role of other contributing cell
types in the bone compartment or by circulating factors
such as liver-derived Notum or other indirect systemic
effects could not be excluded. To determine the source of
NOTUM in cortical bone and the function of osteoblast-
derived NOTUM in vivo, we generated a conditional
Notum-inactivatedmousemodel targeting osteoblasts and
osteocytes. A mouse model with exons 2–8 of Notum
flanked by LoxP sites (Notumflox/flox, Fig. 2A) was used
(16). To achieve inactivation of NOTUM early in the
osteoblast lineage, we generated Runx2-creNotumflox/flox
mice,which expressCre recombinase driven by theRunx2
promoter, a promoter that is expressed specifically in early
osteoblast lineage cells but not in osteoclasts (Fig. 2A) (18).
Runx2-creNotumflox/flox mice had substantial and specific
recombination of the Notumflox allele in bone (Fig. 2B),
resulting in 986 0.4 and 796 9.5% lower NotummRNA
levels in cortical bone of female and male mice, respec-
tively, compared to correspondingNotumflox/floxmice (Fig.
2C). Analyses of isolated calvarial cells, containing a large
proportion of osteoblasts, showed that cells from Runx2-
creNotumflox/flox mice had substantially lower levels of
Notum mRNA expression compared with cells from
Notumflox/floxmice (Fig. 2D). ExpressionofNotummRNAin
bonemarrowmacrophageswas close to thedetection limit
andwas not affected by osteoblast lineage–specificNotum
inactivation (Fig. 2D). These findings demonstrate that
osteoblast lineage–derived NOTUM is the principal
source of NOTUM in cortical bone.
Runx2-creNotumflox/flox mice displayed normal embry-
onic development and were born apparently healthy and
had a normal body weight growth through 17 wk of
age (Fig. 2E). In addition, Runx2-creNotumflox/floxmice had
normal bone length of femur (Fig. 2F) and normalweights
of several visceral organs (Fig. 2G). DXAanalyses revealed
that both male and female Runx2-creNotumflox/flox mice
developed increased total body BMD during sexual
maturation (Fig. 2H). Total femur BMD was also signifi-
cantly increased in both adult male and adult female
Runx2-creNotumflox/floxmice comparedwith corresponding
Notumflox/floxmice (Fig. 2I).Thus,osteoblast-derivedNOTUM
is the principal source of NOTUM in bone and decreases
total body BMD.
Osteoblast-derived NOTUM reduces cortical
but not trabecular bone mass
Detailed CT analyses of the cortical diaphyseal bone in
femur revealed increased cortical bone area (Fig. 3A),
cortical bone thickness (Fig. 3B), and cortical polar mo-
ment of inertia (Fig. 3C) in adult Runx2-creNotumflox/flox
mice compared to control mice. However, neither the
cortical porosity (Fig. 3D) nor the cortical volumetric
BMD (Fig. 3E) were affected in the Runx2-creNotumflox/flox
mice. Furthermore, the cortical thickness and cortical area
of vertebral body L5 were increased in female Runx2-
creNotumflox/flox mice compared to control mice and a
similarnonsignificant trend (P=0.09)wasobserved for the
cortical bone area in male mice (Supplemental Table S2).
The increased amount of cortical bone resulted in a sub-
stantial increase in mechanical strength (maximum load;
Fig. 3F) and whole-bone work-to-fracture (Fig. 3G) of the
cortical bone,whereas the structural stiffness (Fig. 3H)was
not significantly affectedwhen evaluated by using 3-point
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bending in the diaphyseal region of the humerus. Runx2-
creNotumflox/flox male mice had normal BV/TV in both the
distal metaphyseal region of femur (Fig. 3I) and in the L5
vertebral body (Fig. 3J).Runx2-creNotumflox/flox femalemice
had also a normal BV/TV in the distalmetaphyseal region
of femur (Fig. 3I) but a slightly decreased BV/TV in the L5
vertebral body (Fig. 3J). The increased cortical thickness
but not trabecular bone mass is a phenocopy, although
slightly more pronounced, of the heterozygote female
global Notum-inactivated mice. The increased cortical
bone thickness in both the male and the female mice
with osteoblast lineage–specificNotum inactivationwas
the result of an increased periosteal circumference (Fig.
3K), whereas the endocortical circumference was not
reduced (Fig. 3L). However, cortical histomorpho-
metric analyses performed at 17 wk of age did not
identify any significant effects on bone formation rate or
on numbers of osteoblasts or osteoclasts per bone sur-
face (Supplemental Table S3).
Inducible inactivation of Notum increases
cortical periosteal bone formation
Although very informative, the studies using osteoblast
lineage–specific Notum inactivation could not separate
between developmental effects of NOTUM and its effects
on adult bonemetabolism.Therefore, to evaluate the effect
of Notum specifically on adult cortical bone homeostasis
and the underlying mechanisms, we developed a mouse
model with tamoxifen-inducible Notum inactivation
in adult mice. To this end, we bred Notumflox/flox mice
with CAGGCre-ER transgenic mice (19) expressing a
Figure 3. Osteoblast-derived NOTUM reduces cortical but not trabecular bone mass. A–E) Cortical bone area (A), cortical
thickness (B), mean polar moment of inertia (C), cortical porosity (D), and cortical volumetric BMD (E) of the femur as
measured by mCT in Runx2-creNotumﬂox/ﬂox (female, n = 11; males, n = 15) and Notumﬂox/ﬂox (females, n = 13; males, n = 11) mice.
F–H) Maximal load (F max) (F), whole-bone work-to-fracture (G), and (H) structural stiffness (H) of the humerus as measured
by 3-point bending in Runx2-creNotumﬂox/ﬂox (female, n = 11; males, n = 15) and Notumﬂox/ﬂox (females, n = 13; males, n = 11) mice.
All biomechanical data are whole-bone data. I, J ) Trabecular BV/TV in the femur (I) and vertebral body L5 (J ) in Runx2-
creNotumﬂox/ﬂox mice (females, n = 11; males, n = 15) and Notumﬂox/ﬂox mice (females, n = 13; males, n = 11). K , L) Periosteal (K)
and endocortical circumference (L) of the femur as measured by mCT in Runx2-creNotumﬂox/ﬂox (females, n = 11; males, n = 15)
and Notumﬂox/ﬂox (females, n = 13; males, n = 11) mice. Unless otherwise stated, the results refer to 17-wk-old mice. All values are
given as means 6 SEM. *P , 0.05, **P , 0.01 vs. Notumﬂox/ﬂox mice (Student’s t test).
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tamoxifen-inducible Cre-mediated recombination system
(Fig. 4A). We have previously shown that CAGGCre-ER
mice do not have a skeletal phenotype (32). All mice
evaluated were treated with the same tamoxifen re-
gime, using daily intraperitoneal injections during 3
consecutive days and the phenotype of CAGGCre-
ER-Notumflox/flox and Notumflox/flox mice were compared
(Fig. 4A). The Notum mRNA levels in cortical bone
were substantially lower (263 6 5%; P , 0.01) in
tamoxifen-treated CAGGCre-ER-Notumflox/flox mice
compared with tamoxifen-treated Notumflox/flox mice,
demonstrating efficient Notum inactivation (Fig. 4B).
To determine the skeletal phenotype in the inducible
Notum knockout mice, 11-wk-old Notumflox/flox and
CAGGCre-ER-Notumflox/flox mice were treated with ta-
moxifen and the phenotype was evaluated 31 d after
the first tamoxifen dose. The inducible inactivation of
Notum did not affect body weight, weights of liver, go-
nadal fat, kidney, spleen or uterus, or the lengths of femur
or tibia (Supplemental Table S4). Detailed skeletal analy-
ses using DXA and CT revealed that the total femur BMD
(P , 0.05) and several diaphyseal cortical bone mass pa-
rameter (cortical area, cortical thickness, and cortical mo-
mentof inertia;P,0.05) butnotBV/TVin themetaphyseal
region of tibia were significantly increased in tamoxifen-
treated CAGGCre-ER-Notumflox/flox mice compared with
tamoxifen-treatedNotumflox/floxmice (Table 1).
Dynamic cortical histomorphometry was performed
to determine if inducible Notum inactivation increased
cortical bone thickness via increased cortical bone
formation. Periosteal mineralized surface (+32 6 4%;
P , 0.01; Fig. 4C), mineral apposition rate (+65 6 16%;
P, 0.05; Fig. 4D), andbone formation rate (+1136 25%;
P , 0.01; Fig. 4E) were substantially increased in
tamoxifen-treated CAGGCre-ER-Notumflox/flox mice com-
pared with tamoxifen-treated Notumflox/flox mice. In con-
trast, endocortical bone formation was not significantly
affected by inducible Notum inactivation (Fig. 4F–H).
Static histomorphometry revealed that the periosteal
number of osteoblasts (+183 6 68%; P , 0.05) and the
periosteal surface covered by osteoblasts (+183 6 66%;
P , 0.05) were significantly increased by inducible
Notum inactivation, whereas the number of osteoblasts
on the endocortical sidewas unchanged (Table 2). These
mechanistic studies using inducible Notum inactivation
demonstrate that Notum deficiency increases bone for-
mation at the periosteal, but not at the endocortical, side
of the cortical bone. For further mechanistic studies in-
cluding analyses of serum bone markers and gene
transcripts, Notumflox/flox and CAGGCre-ER-Notumflox/flox
mice were induced with tamoxifen and evaluated
11 d after the first tamoxifen dose. Although serum
levels of the bone resorption marker CTX fragments
(Fig. 4I) and the mRNA levels of the osteoclast-specific
transcript Acp5 in cortical bone (Fig. 4J) were reduced,
neither the number of periosteal osteoclasts nor the
number of endocortical osteoclasts were significantly
altered by Notum inactivation (Table 2). Thus, inducible
Notum inactivation does not seem to influence the
number of osteoclasts, but we cannot exclude the
possibility that an inhibitory effect on osteoclast
activity might have contributed to increased cortical
bone thickness.
Silencing of NOTUM increases
osteoblast differentiation
To determine if osteoblast-derived NOTUM has the ca-
pacity to exert local effects on osteoblasts, Notum expres-
sionwassilenced inosteoblastsusing thepreosteoblast cell
line MC3T3-E1. The cells were silenced 1 and 3 d after
seeding and treated with osteogenic medium for 7 d,
starting 24 h after the second silencing. Expression of
NotummRNAwas decreased by 826 9% (P, 0.001) and
956 2% (P, 0.05) after the first and second silencing (Fig.
5A). Analyses of osteoblast differentiation showed that
silencing of Notum resulted in enhanced mRNA expres-
sion ofAlpl already 24h after the second silencing (Fig. 5B)
and an increased ALP staining (Fig. 5C) and a 7-fold
increase ofALP activity (Fig. 5D) at the end of the cultures,
indicating that NOTUM is a negative regulator of osteo-
blastic differentiation. These findings clearly demonstrate
that osteoblast-derived NOTUM has the capacity to exert
local effects on osteoblast differentiation.
Recombinant NOTUM protein does not affect
osteoclast differentiation or activity
Because theNOTUMexpression is very low in osteoclasts,
we wanted to explore the possibility that paracrine or en-
docrine NOTUM might exert effects on osteoclasts. To
determine if preosteoclasts or osteoclasts have the capacity
to respond to NOTUM, we treated BMMs with M-CSF/
RANKL in the absence and presence of recombinant hu-
man NOTUM. First, we demonstrated that the used
recombinant humanNOTUMhad effective lipase activity
(Supplemental Fig. S3).RecombinanthumanNOTUMdid
not affect the formation of TRAP-positive multinucleated
osteoclasts (Fig. 5E) or M-CSF/RANKL-induced expres-
sion of the osteoclastic genes Acp5, Ctsk, and Nfatc1 (Fig.
5F–H), when BMMs were cultured on plastic dishes.
Recombinant NOTUM affected neither osteoclast forma-
tion onbonedisc as assessedby release of TRAP5b (Fig. 5I)
nor osteoclast resorption activity analyzed by release of
CTX (Fig. 5J), suggesting that NOTUMdoes not exert any
direct effects on osteoclasts. These data, however, do not
exclude the possibility that NOTUM could have indirect
effects on osteoclasts in vivo.
Large-scale human genetic analyses reveal
that the NOTUM locus is associated with BMD
To determine if the NOTUM locus is also associated with
bone mass in humans, we used the complete UK Biobank
data set, currently the most powerful available re-
source for human genetic analyses of a bone phenotype
(https://www.biorxiv.org/content/early/2017/09/27/194944). We
searched for possible associations between imputed SNPs
specifically in theNOTUM locus (defined as6 25 kb from
the gene start and end limits) and BMD as estimated by
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Figure 4. Inducible inactivation of the Notum gene increases cortical periosteal bone formation. A) Schematic drawing of the
inducible Notum inactivation model. B) mRNA expression analyses of Notum in cortical bone in CAGGCre-ER-Notumﬂox/ﬂox mice
(continued on next page)
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quantitative ultrasound of the heel (eBMD; available in
445,921 European subjects). In total, we tested 125 SNPs
with a minor allele of .1% and identified 2 independent
genetic signals located upstream ofNOTUM (Table 3 and
Supplemental Fig. S4A, B) both associated with a P value
of ,10210, providing compelling statistical evidence that
genetic variation arising from the NOTUM locus is asso-
ciated with eBMD in humans. One of the identified SNPs,
rs35344256 (Supplemental Fig. S4A; C allele associ-
ated with reduced eBMD), is a common variant with
minor allele frequency of 31%, whereas the other SNP,
rs147901986 (Supplemental Fig. S4B; G allele associated
with increased eBMD), is a low-frequency variant with
minor allele frequency of 2.9% (Table 3).
DISCUSSION
NOTUM is a secreted WNT lipase reducing WNT ac-
tivity (9, 10). As the role of NOTUM in vivo is essentially
unknown, we developed global, cell-specific, and in-
ducible Notum-inactivated mouse models. We herein
demonstrate that osteoblast lineage–derived NOTUM
is a crucial determinant specifically of cortical bone
mass and strength via regulation of periosteal bone
formation in mice and that genetic variants in the NO-
TUM locus are robustly associated with BMD in
humans.
WNT proteins signal through both the canonical
WNT pathway and the noncanonical WNT pathways
(1, 2, 14, 33, 34). Activation of canonical b-catenin sig-
naling increases bone mass, and rare human genetic
mutations affecting bone have been identified in com-
ponents of the canonical and noncanonical WNT sig-
naling machinery (1, 4, 35–39). Recent in vitro studies
demonstrate that NOTUM inactivates WNTs by re-
moving their attached lipid group essential for activa-
tion of Frizzled receptors (9, 10). To evaluate if NOTUM
may be a local factor in bone, we first developed and
characterized a mouse model with global Notum in-
activation. Because a majority of Notum2/2 mice died
during embryonal development, it was not possible to
determine the physiologic role of NOTUM for any
phenotype in adult Notum2/2 mice. However, hetero-
zygous Notum-inactivated mice, having significantly
reduced Notum expression in multiple tissues, were
born apparently healthy and displayed a normal body
weight and longitudinal bone growth. The female mice
with heterozygous global Notum inactivation had
increased cortical bone thickness and bone strength
but normal BV/TV. Although our studies using het-
erozygous female mice with global Notum inactivation
indicated that NOTUM reduces cortical but not tra-
becular bone mass, these studies were difficult to
interpret. First, a majority of homozygous Notum-
inactivated mice died during embryonic development,
demonstrating that NOTUM is required for normal
development and that it therefore is not possible to use
this mousemodel to determine the effect of NOTUMon
adult bone metabolism. Second, although female mice
with global Notum inactivation had increased cortical
bone thickness, no significant bone phenotype was
observed in heterozygous male mice. Finally, the ex-
periments using global Notum inactivation could not
determine the source of NOTUM with an impact on
cortical bone. BecauseNotum expressionwas high in the
cortical bone, we hypothesized that the cortical bone
phenotype in the heterozygote female Notum-inacti-
vatedmicemight be caused by lack ofNotum expression
by osteoblast lineage cells in cortical bone. However, a
role of other contributing cell types in the bone com-
partment or by circulating factors, such as liver-derived
Notum, or other indirect systemic effects could not be
excluded using this mouse model.
To determine if the relatively highNotum expression
in cortical bone is osteoblast-derived and to determine
the in vivo role of osteoblast-derived NOTUM, we de-
veloped a conditional Notum-inactivated mouse model
with inactivation of Notum in both osteoblasts and os-
teocytes. Using this model, we clearly demonstrated
that osteoblast lineage cells are the principal source of
NOTUM in cortical bone, and we next determined the
functional role of osteoblast-derived NOTUM. In con-
trast to homozygous mice with global Notum in-
activation, thosewith osteoblast lineage–specificNotum
inactivation were born healthy and displayed a normal
body weight and longitudinal bone growth. These
findings demonstrate that the severe developmental
effects in the global Notum-inactivated homozygous
mice are caused by lack of NOTUM in other cells than
osteoblast lineage cells. CT analyses, separating the
cortical and trabecular bone compartments revealed
that both adult male and adult female mice with oste-
oblast lineage–specific inactivation of Notum had in-
creased cortical bone thickness in the long bones,
whereas no increase was observed on BV/TV in the
(22-wk-old male mice, n = 10) and Notumﬂox/ﬂox mice (n = 12). C–E) Mineralizing surface per bone surface (C), mineral
apposition rate (D), and bone formation rate per bone surface (E) on the periosteal side of tibia as measured by
histomorphometry in CAGGCre-ER-Notumﬂox/ﬂox mice (15-wk-old female mice, n = 11) and Notumﬂox/ﬂox mice (n = 6). F–H)
Mineralizing surface per bone surface (F), mineral apposition rate (G), and bone formation rate per bone surface (H) on the
endocortical side of tibia as measured by histomorphometry in CAGGCre-ER-Notumﬂox/ﬂox mice (15-wk-old female mice, n = 11)
and Notumﬂox/ﬂox mice (n = 6). I) Levels of procollagen type I N-terminal propeptide (P1NP, left) and (CTX) fragments (right)
measured in serum in CAGGCre-ER-Notumﬂox/ﬂox mice (22-wk-old male mice, n = 12) and Notumﬂox/ﬂox mice (n = 10). J ) mRNA
expression analyses of ALP (Alpl, left) and TRAP (Trap/Acp5, right) in cortical bone of CAGGCre-ER-Notumﬂox/ﬂox mice (22-wk-old
male mice, n = 10) and Notumﬂox/ﬂox mice (n = 12). All values are given as means 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001 vs.
Notumﬂox/ﬂox mice (Student’s t test).
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vertebrae or in the long bones. Although slightly more
pronounced, this specific cortical bone phenotype in
mice with osteoblast lineage–specific Notum inactiva-
tion is very similar to the cortical bone phenotype
observed in the female mice with heterozygous global
Notum inactivation, supporting the concept that
osteoblast-derivedNOTUM ismediating the effects on
cortical bone thickness.
Three-point bending analyses revealed substantially
increased whole-bone mechanical bone strength in mice
with osteoblast lineage–specific inactivation of Notum
compared with control mice, demonstrating that the in-
creased cortical bone thickness resulted in increased bone
strength. It is a limitation with the present study that the
cortical bone quality was only evaluated by cortical
porosity measurements, whereas no analyses of the tissue
material properties were performed, precluding state-
ments on the corticalbonequality.Another limitationwith
the present study is that the cortical tissue organization
estimated by informative collagen type I orientation
analyseswasnotperformed (40–42).The increasedcortical
bone thickness in both the male and the female mice with
osteoblast lineage–specific Notum inactivation was the
result of an increased periosteal circumference, whereas
the endocortical circumference was not reduced, sug-
gesting that the increased cortical bone thickness was
caused by cortical periosteal bone formation. However,
the lack of significant effects on cortical bone formation
rates and number of osteoclasts in 17-wk-old adult
mice with lifelong osteoblast lineage–specific Notum
Figure 5. Silencing of NOTUM in MC3T3-E1 cells increases osteoblastic differentiation. A) mRNA expression analyses of Notum in
MC3T3-E1 cells 24 h after ﬁrst (d 2) and second (d 4) silencing using siRNA. B) mRNA expression analyses of Alpl in MC3T3-E1
cells 24 h after second silencing of Notum using siRNA. C) ALP staining of MC3T3-E1 cells after silencing of Notum and cultured
in osteogenic medium for 7 d. D) ALP enzymatic activity in MC3T3-E1 cells after silencing of Notum and cultured in osteogenic
medium for 7 d. E) TRAP staining of osteoclasts cultured in the presence or absence of recombinant NOTUM protein for 3 d.
F–H) Expression of Acp5 (F), Ctsk (G), and Nfatc1 (H) in osteoclasts cultured in the presence or absence of recombinant
NOTUM for 3 d. I) TRAP5b protein released into osteoclast culture media during d 7–10 of culture on bone discs in the
presence or absence of recombinant NOTUM. J ) CTX released into osteoclast culture medium during d 7–10 of culture on bone
discs in the presence or absence of recombinant NOTUM. M, M-CSF; RL, RANKL; siSCR, control scramble siRNA; siNOTUM,
NOTUM-speciﬁc siRNA. All values are given as means6 SEM. *P, 0.05, **P, 0.01, ***P, 0.001 vs. siSCR [Student’s t test (A, B,
D)]; ***P , 0.001 vs. the M treatment [1-way ANOVA and Tukey’s multiple comparison test (F–H)]; n = 4 wells/treatment. All
cell culture experiments were repeated at least twice with similar results.
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inactivation indicated that the increased cortical bone
thickness of these mice was a result of effects occurring
earlier in life. Therefore, to evaluate the effect of NOTUM
on adult cortical bone homeostasis and the underly-
ing mechanisms, we developed a mouse model with
tamoxifen-inducibleNotum inactivation in adult mice. An
increase specifically of cortical bone mass was observed
only 4 wk after the inducible Notum inactivation in adult
mice, excluding confounding developmental effects and
demonstrating that endogenous NOTUM exerts crucial
effects on cortical bone homeostasis in adult mice. The
mechanistic studiesusing themousemodelwith inducible
inactivation of Notum revealed that NOTUM deficiency
increases periosteal bone formation as a result of a com-
bination of increased periosteal mineralized surface,
reflecting the number of active osteoblasts, and increased
periostealmineral apposition rate, reflecting the activity of
osteoblasts. An effect on cortical periosteal bone formation
was further supported by the observed increased num-
ber of osteoblasts on the periosteal surface in mice with
inducible Notum inactivation. Collectively, the acute
mechanistic data, using inducible Notum inactivation,
demonstrate that the increased periosteal cortical circum-
ference, observed in mice with lifelong chronic osteoblast
lineage–specific inactivation ofNotum, is primarily caused
by increased periosteal bone formation.
A local effect of osteoblast-derived Notum on osteo-
blasts is supported by our finding that Notum silencing
enhanced osteoblast differentiation in culturedMC3T3-E1
osteoblasts. In contrast, very low Notum expression was
observed in osteoclast cultures and recombinant human
NOTUM did not exert any significant direct effect on
osteoclast formation or activity in vitro. Although serum
levels of the bone resorption marker CTX and the mRNA
levels of the osteoclast-specific transcript Acp5 in cortical
bone were reduced by inducible Notum inactivation, we
were unable to detect any decrease of the number of os-
teoclasts in cortical bone. Thus, NOTUMdoes not seem to
exert any effect on osteoclastogenesis in cortical bone. Our
findings overall demonstrate that the principal mecha-
nism for the increased cortical bone thickness in Notum-
inactivatedmice is an increased periosteal bone formation
via depletion of local inhibitory effects of osteoblast-
derived NOTUM on osteoblast number and activity.
Very similar increases on cortical bone thickness and
cortical bone strength were observed in male and female
mice for themousemodelwith osteoblast lineage–specific
Notum inactivation. In contrast, for the mouse model with
heterozygous global Notum inactivation, a significant
cortical bone phenotype was only observed in female
mice, suggesting that femalemicemight bemore sensitive
to changes in Notum expression. It is a limitation with the
present study that possible sex differences in the effect on
cortical bone thickness were not investigated in the in-
ducible Notum-inactivated mouse model.
Cortical bone mass is a major determinant of bone
strength and therefore of susceptibility to fractures (3, 43).
With aging, the mass of cortical bone may decrease more
than the mass of trabecular bone, and fractures occurring
in older persons result to a large extent from cortical bone
fragility (43, 44). Although progress has been made in
therapeutic approaches to reduce the risk of vertebral
fracture (which occurs at sites rich in trabecular bone),
currently available treatments do little to reduce the risk of
nonvertebral fracture, which results mostly from cortical
bone fragility (4, 43, 45, 46). Thus, there is amedicalneed to
improve the therapy for nonvertebral fractures, and our
present finding that osteoblast-derived Notum reduces
cortical bone mass suggests that methods inhibiting the
effect of NOTUM might increase cortical bone mass and
thereby reduce nonvertebral fracture risk.
Mice with osteoblast- or osteocyte-specific inactivation
of Wntless (Wls, previously known as Gpr177), which is
required for the secretion ofWNT ligands from cells, have
substantially reduced bone mass, illustrating the crucial
role of osteoblast lineage–derived WNTs for bone ho-
meostasis (47). In contrast to mice with osteoblast
lineage–specific Wls inactivation (displaying a marked
reduction of both trabecular and cortical bone mass) (47),
osteoblast lineage–specific Notum inactivation resulted
specifically in increased cortical bone thickness without
affecting trabecular bone mass. Combined, these findings
suggest that NOTUM mainly renders WNTs inactive in
cortical bone, and this notion is supported by our obser-
vation that theNotum expression is higher in cortical than
in trabecular bone. The fact that patients with Pyle’s dis-
ease, caused by recessive mutation in the SFRP4 gene,
encoding a soluble WNT inhibitor, have thin cortical but
dense trabecular bone, further demonstrates that WNTs
and WNT modulators exert site-specific effects in the
skeleton (46).
Previous studies have demonstrated that osteoblast-
derivedWNT16 increases cortical but not trabecular bone
mass, and it is therefore possible that osteoblast-derived
WNT16 is inactivated by osteoblast-derived NOTUM in
cortical bone (2, 48). We recently observed that inducible
TABLE 3. Genetic variants in the NOTUM locus are associated with BMD
SNP Chr Position A1 A2 AF b SE P N
rs35344256 17 79934194 C A 0.69 20.0134 0.0020 1.5E211 445921
rs147901986 17 79921522 G A 0.97 0.0386 0.0059 4.6E211 445921
Large-scale human genetic analyses revealed that genetic variants in the NOTUM locus are associated
with BMD. We speciﬁcally searched for possible associations between imputed SNPs (minor allele fre-
quency .1%) in the NOTUM locus 625 kb (in total 125 SNPs with a minor allele frequency .1% were
evaluated) and BMD as estimated by quantitative ultrasound of the heel. A1, effect allele; A2, other allele;
AF, allele frequency of allele 1. Independent SNPs associated with BMD and with P , 1 3 10210. b given
as SD change in eBMD per effect allele.
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Wnt16 inactivation in adult mice reduces periosteal corti-
cal bone formation (32). In addition, we herein demon-
strate that inducible inactivation of the WNT lipase
Notum in adult mice increases periosteal cortical bone
formation, suggesting that there may be a local periosteal
interaction between WNT16 and NOTUM for the regula-
tion of bone formation. We propose that in adult mice,
WNT16-mediated periosteal bone formation might be
inhibited by a localNOTUM-mediated negative feedback.
A role of intact palmitoleoylation of WNTs for perios-
teal bone growth is supported by our recent finding that
inhibition of Porcupine, the enzyme responsible for
palmitoleoylation of WNTs, reduces periosteal but not
endocortical bone formation (49). The trabecular bone
phenotype in mice with osteoblast lineage–specific inac-
tivationofWlsmost likely ismediatedby loss ofWNTsnot
inactivated by NOTUM within the trabecular bone mi-
croenvironment (47). Collectively, these findings demon-
strate that WNTs may exert compartment-specific effects
on bone homeostasis and that NOTUM most likely inac-
tivates WNTs with a crucial effect specifically on cortical
bone.
It has recently been reported that substances inhibiting
the lipase activity of NOTUM increased cortical bone
thickness (13, 50, 51). These substances, selected based on
their capacity to inhibit lipase activity and canonical sig-
naling specifically by WNT3A, increased cortical bone
thickness mainly via an increased endocortical bone for-
mation, whereas inactivation of endogenous NOTUM in
the present study increased cortical bone thicknessmainly
via increased periosteal bone formation. This difference in
the predominant cortical bone surface involved might
be caused by differences in the effects of inactivation of
endogenous NOTUM and the effects of pharmacologi-
cal inhibition of lipase activity, resulting in enhanced
WNT3A-mediated canonical signaling. First, endogenous
NOTUMmayexert lipase independent effects; second, the
lipase substrate specificity, both regarding WNTs known
to control cortical bone homeostasis such as WNT16 and
other non-WNTproteins,maydiffer between endogenous
NOTUM and the pharmacological effect of the developed
substances.
Finally, we evaluated if theNOTUM locus is associated
with bone mass also in humans. To this end, we used
the recently released complete UK Biobank data set (n =
445,921 European subjects) to test genetic variation in the
NOTUM locus for association with eBMD variation in the
most powered setting available. We identified 2 indepen-
dent genetic variants in the NOTUM locus that are asso-
ciated with eBMD. This finding is the first indication that
the NOTUM locus is involved in the regulation of bone
mass also in humans. Subsequent studies assessing
whether these genetic variants in the NOTUM locus are
specifically associated with cortical bone thickness are
warranted in deeper phenotyped cohorts assessed by
computer tomography.
In summary, we demonstrate that osteoblast-derived
NOTUM is an essential regulator of cortical bonemass via
effects on periosteal bone formation in adultmice and that
genetic variation in the NOTUM locus is associated with
BMD in humans. Therapies targeting osteoblast-derived
NOTUMmay constitute useful and specific treatments to
reduce the risk of nonvertebral fractures.
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